Correction to: Nature Cancer https://doi.org/10.1038/s43018-023-00630-y, published online 21 September 2023.
In the version of the article initially published, the affiliation of Ryan Cheng was incorrect and has now been updated to the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Miyazaki, I., Odintsov, I., Ishida, K. et al. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nat Cancer 4, 1526 (2023). https://doi.org/10.1038/s43018-023-00663-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00663-3
